Aromatase inhibitors in infertile patients: effects on seminal parameters, serum and seminal plasma testosterone levels, and estradiol levels during short-term follow-up

Basit Öğe Kaydı
dc.contributor.authorBasar, M. Murad
dc.contributor.authorTuglu, Devrim
dc.date.accessioned2020-06-25T17:48:20Z
dc.date.available2020-06-25T17:48:20Z
dc.date.issued2009
dc.departmentKırıkkale Üniversitesi
dc.description.abstractAim: To evaluate the effects of an aromatase inhibitor (anastrozole) on seminal parameters, and on serum and seminal plasma testosterone/estradiol ratios in infertile patients, as well as to clarify its place among empirical infertility treatment modalities. Patients and Methods: The study included 32 patients with spermatozoa numbering > 5 million/mL in ejaculate and a serum testosterone/estradiol ratio < 0.14. Anastrozole, an aromatase-inhibiting agent, was given (1 mg b.i.d.) and patients were re-evaluated 2 months later based on semen analysis, and measurements of serum and seminal plasma testosterone and estradiol levels. Results: Semen analysis parameters before and after treatment, respectively, were as follows: number of spermatozoa: 12.4 +/- 4.1 million/mL and 22.3 +/- 5.7 million/mL; motility: 33.4 +/- 4.2% and 47.6 +/- 7.4%; normal morphology: 5.4 +/- 1.3% and 8.9 +/- 2.7%. Differences between the values before and after treatment were statistically significant (P < 0.05). Serum testosterone level was 4.1 +/- 1.2 ng/mL, estradiol level was 52.1 +/- 9.4 pg/mL, and testosterone/estradiol ratio was 0.13 +/- 0.03 at the beginning of treatment. These values were 3.2 +/- 0.6 ng/mL, 68.4 +/- 7.3 pg/mL, and 0.05 +/- 0.001, respectively, in seminal plasma. Following 2 months of anastrozole treatment, testosterone and estradiol levels, and the testosterone/estradiol ratio showed statistically significant changes in serum and seminal plasma. While testosterone levels significantly increased, estradiol levels decreased (serum P-T = 0.001, P-E2 = 0.001; seminal plasma P-T = 0.001, P-E2 = 0.001). Conclusion: Aromatase inhibitors are a potential treatment method for infertile male patients with increased plasma estradiol levels and decreased plasma testosterone/estradiol ratios.en_US
dc.identifier.citationBaşar, M. M., Tuğlu, D. (2009). Aromatase inhibitors in infertile patients: effects on seminal parameters, serum and seminal plasma testosterone levels, and estradiol levels during short-term follow-up. Turkish Journal of Medical Sciences, 39(4), 519 - 524.en_US
dc.identifier.doi10.3906/sag-0802-10
dc.identifier.endpage524en_US
dc.identifier.issn1300-0144
dc.identifier.issn1303-6165
dc.identifier.issue4en_US
dc.identifier.scopus2-s2.0-69249133355
dc.identifier.scopusqualityQ1
dc.identifier.startpage519en_US
dc.identifier.trdizinid93755
dc.identifier.urihttps://doi.org/10.3906/sag-0802-10
dc.identifier.urihttps://hdl.handle.net/20.500.12587/4413
dc.identifier.volume39en_US
dc.identifier.wosWOS:000271094700004
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakTR-Dizin
dc.language.isoen
dc.publisherTubitak Scientific & Technical Research Council Turkeyen_US
dc.relation.ispartofTurkish Journal Of Medical Sciences
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectMale infertilityen_US
dc.subjectestradiolen_US
dc.subjecttestosteroneen_US
dc.subjectaromatase inhibitorsen_US
dc.titleAromatase inhibitors in infertile patients: effects on seminal parameters, serum and seminal plasma testosterone levels, and estradiol levels during short-term follow-upen_US
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
5597ddad-bcea-4345-b760-b3697a71b925.pdf
Boyut:
77.05 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam metin/Full text
İndir

Koleksiyon

WOS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu